SPECT/CT imaging to measure radiation dose during Pluvicto (177Lu‑PSMA‑617) treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a non‑interventional imaging study enrolling men who are scheduled to receive 177Lu‑PSMA‑617 therapy. Participants will undergo SPECT/CT imaging according to a dosimetry imaging protocol so absorbed radiation dose to tumors and normal organs can be calculated. Those dose estimates will be compared with clinical response measures and with observed organ toxicities to look for dose‑response and dose‑toxicity relationships. The study aims to inform personalized dosing and safety monitoring for future patients receiving this radioligand therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \* 177Lu-617 PSMA treatment scheduled for mCRPC

  * Clinically stable as determined by the nuclear medicine clinicians
  * Male
  * ≥ 18 years of age
  * Willing and able to provide informed consent

Exclusion Criteria:

* Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed

Where it's running

• University of Michigan Comprehensive Cancer Center
  Ann Arbor, Michigan, United States Recruiting

Study contacts

• Principal investigator: Yuni K Dewaraja — University of Michigan Rogel Cancer Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing Different Dosing Schedules of Lutetium-177Lu PSMA RLT in Advanced Prostate Cancer

  This trial tests if spacing out Lutetium-177Lu PSMA RLT doses adapts to the patient and improves quality of life without shortening life in men with advanced, hormone-resistant prostate cancer.

  Recruiting at 105 sites Phase 3 Alliance for Clinical Trials in Oncology · Anchorage, Alaska and 141 other locations · NCT07200830

• New ACK1-blocking pill (R)-9bMS for advanced prostate cancer

  This phase 1 trial will test whether the oral ACK1 inhibitor (R)-9bMS is safe and tolerable in men with metastatic castration-resistant prostate cancer who no longer respond to enzalutamide or abiraterone.

  Recruiting Phase 1 TechnoGenesys, Inc. · Madison, Wisconsin · NCT06705686

• Intensified treatment for advanced prostate cancer using 177Lu-PSMA-617

  This study is testing a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that doesn't respond to hormone therapy to see if it works better than the usual treatments.

  Recruiting at 2 sites Phase 2 University of Washington · San Francisco, California and 2 other locations · NCT06526299

• Cell therapy combined with enzalutamide for advanced prostate cancer

  This study is testing a new combination of cell therapy and a medication called enzalutamide to see if it helps people with advanced prostate cancer live better and longer.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06236139

• Using a new imaging test for prostate cancer before treatment

  This study is testing a new imaging scan to see how well it can show the spread of advanced prostate cancer before starting treatment.

  Recruiting at 2 sites Phase 4 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT06099093

• Using abemaciclib before a radioactive treatment for advanced prostate cancer

  This study is testing if taking abemaciclib before a radioactive treatment can help men with advanced prostate cancer feel better and improve their treatment results.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT05113537

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.